A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer.

Kuemmel, S; Campone, M; Loirat, D; Lopez, RL; Beck, JT; De Laurentiis, M; Im, SA; Kim, SB; Kwong, A; Steger, GG; Adelantado, EZ; Duhoux, FP; Greil, R; Kuter, I; Lu, YS; Tibau, A; Özgüroğlu, M; Scholz, CW; Singer, CF; Vega, E; Wimberger, P; Zamagni, C; Couillebault, XM; Fan, L; Guerreiro, N; Mataraza, J; Sand-Dejmek, J; Chan, A.

Clin Cancer Res. 2022 Jan 1;28(1):106-115. doi: 10.1158/1078-0432.CCR-20-3955. Epub 2021 Oct 6.

https://pubmed.ncbi.nlm.nih.gov/34615719/